Clinical Trial Update: Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) [Phase 3]

View source ↗

Summary

A Phase 3 completed trial assessing immunogenicity bridging between an investigational monovalent HPV vaccine and the corresponding component of Gardasil, the q…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts

Drugs mentioned

• Gardasil (human papillomavirus vaccine)
• Investigational monovalent HPV vaccine (unspecified type)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancer, Genital Warts | Phase 3 | Status: COMPLETED